<DOC>
	<DOC>NCT03075267</DOC>
	<brief_summary>A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of PT003 in healthy Chinese adult subjects</brief_summary>
	<brief_title>Phase I Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administration and After Chronic Administration for 7 Days</brief_title>
	<detailed_description>A Phase I, Randomized, Double-Blind, Parallel Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following a Single Administration and After Chronic Administration for 7 Days</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male and female Chinese subjects 1845 years of age Females of childbearing potential must agree to be abstinent or else use one of the following medically acceptable forms of contraception A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. A male subject with female partner of child bearing potential must agree to use one additional form of medically acceptable contraception Be in good general health as assessed at Screening and have no clinically significant abnormal labs at Screening . Pregnant or nursing female subjects or subjects who are trying to conceive Subjects with clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study; Subjects with a history of ECG abnormalities Subjects who have cancer that has not been in complete remission for at least 5 years; Male subjects with symptomatic prostatic hypertrophy that is clinically significant in the opinion of the Investigator; Male subjects with a transurethral resection of the prostate or full resection of the prostate within 6 months prior to Screening; Males with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator; Subjects with a diagnosis of glaucoma that in the opinion of the Investigator has not been adequately treated; History of substancerelated disorders within 1 year of Screening; History of smoking or the use of nicotine containing products or electronic cigarettes within 3 months of Screening by selfreporting; A positive alcohol breathalyzer or urine drug screen for drugs of abuse at the Screening Visit or at the beginning of each inpatient period; Treatment with any prescription or nonprescription drugs (including vitamins, herbal, and dietary supplements) within 30 days Positivity for human immunodeficiency virus (HIV) or Hepatitis B surface antigen (HbsAg) or positive hepatitis C antibody at Screening Positive for Syphilis Antibody Subjects with any flulike syndrome or other respiratory infections Recently vaccinated with an attenuated live virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>